Suppr超能文献

卡马西平诱导的严重皮肤药物不良反应:马来西亚儿童与成人 21 年对比研究。

Carbamazepine-Induced Severe Cutaneous Adverse Drug Reactions: A 21-Year Comparison Between Children and Adults in Malaysia.

机构信息

National Pharmaceutical Regulatory Agency, Ministry of Health, Malaysia.

出版信息

J Clin Pharmacol. 2023 Oct;63(10):1126-1132. doi: 10.1002/jcph.2289. Epub 2023 Jul 5.

Abstract

Severe cutaneous adverse drug reactions (SCARs) are a life-threatening condition. We aimed to identify all carbamazepine-induced SCARs voluntarily reported to the Malaysian pharmacovigilance database and to compare between children and adults. Adverse drug reaction reports for carbamazepine were extracted from 2000 to 2020, and divided into 2 groups, that is, children (aged 0-17 years) and adults (aged 18 years and above). Age, sex, race, and carbamazepine dose were analyzed using multiple logistic regression. Of 1102 carbamazepine adverse drug reaction reports, 416 reports were SCARs (99 children, 317 adults). Stevens-Johnson syndrome and toxic epidermal necrolysis were the main SCAR types for both age groups. Median time-to-onset for any type of SCAR was 13 days, regardless of age. In children, Malay individuals were 3.6 times more likely to report SCARs (95% confidence interval, 1.356-9.546; P = .010) compared to the Chinese population. In adults, carbamazepine-induced SCARs were reported as 3.6 times higher in those with a daily dose of 200 mg or less as compared to a daily dose of 400 mg or more. (95% confidence interval, 2.257-5.758; P < .001) Carbamazepine-induced SCARs reported in Malaysia were predominantly Stevens-Johnson syndrome or toxic epidermal necrolysis, with the majority in Malay individuals. Initiation therapy needs close monitoring between 2 weeks and 1 month.

摘要

严重的药物不良反应(SCARs)是一种危及生命的疾病。我们旨在确定所有自愿向马来西亚药物警戒数据库报告的卡马西平诱导的 SCARs,并比较儿童和成人之间的差异。从 2000 年到 2020 年,从数据库中提取了卡马西平的药物不良反应报告,并将其分为两组,即儿童(0-17 岁)和成人(18 岁及以上)。使用多因素逻辑回归分析年龄、性别、种族和卡马西平剂量。在 1102 例卡马西平药物不良反应报告中,有 416 例为 SCAR(99 例儿童,317 例成人)。史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症是两个年龄组的主要 SCAR 类型。无论年龄大小,任何类型的 SCAR 的中位发病时间均为 13 天。在儿童中,与中国人群相比,马来人报告 SCAR 的可能性高 3.6 倍(95%置信区间,1.356-9.546;P = 0.010)。在成人中,与每日剂量为 400 mg 或更高相比,每日剂量为 200 mg 或更低的患者报告卡马西平诱导的 SCAR 风险高 3.6 倍(95%置信区间,2.257-5.758;P<0.001)。在马来西亚报告的卡马西平诱导的 SCAR 主要是史蒂文斯-约翰逊综合征或中毒性表皮坏死松解症,大多数是马来人。起始治疗需要在 2 周至 1 个月之间密切监测。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验